SOTIO Biotech is a clinical-stage immuno-oncology company headquartered in Prague, Czech Republic. The company is developing a series of novel cancer immunotherapies focusing on next-generation pd-1 inhibitory cytokines, CAR-T cell therapies, and antibody-drug couplings (adc's).Sotio's proprietary technologies are designed to improve the efficacy and safety of these immunotherapies, potentially providing new treatment options for patients with a variety of cancers.
Key Products and Technologies
SOT201.A new generation of PD-1 inhibitory cytokines designed to overcome the limitations of existing PD-1 inhibitors by targeting unique epitopes on the PD-1 receptor.
CAR-T cell therapy:: Sotio is developing a proprietary technology for making CAR-T cell therapies that are more effective and longer-lasting than existing therapies.
Antibody-drug coupling (adc). Sotio is developing a new generation of adc designed to improve the efficacy and safety of adc through the use of more effective linkers and payloads.
Clinical Trials.
SOTIO is currently conducting several clinical trials to evaluate its novel immunotherapies in a variety of cancers. The company is also actively developing new product candidates.
Partnerships and cooperation
SOTIO partners with leading pharmaceutical companies and research institutions to support their clinical development and commercialization efforts.
financial position
SOTIO has a strong financial position and financial backing from leading investors. The company is well positioned to advance its pipeline through clinical development and commercialization.
Future prospects
SOTIO is at the forefront of developing the next generation of cancer immunotherapies. The company's pipeline has the potential to address unmet needs in cancer treatment and has the potential to revolutionize the way cancer is treated.
